Annotated highest variance abstracts citing {'original': '[Ii]mmunother'}

20029360

Cancer vaccines for non-small-cell lung cancer.
M Palma, A Choudhury, H Mellstedt
(Department of Oncology, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Solna, Sweden.)
Minerva Chir

lung cancer is globally the second most_common form of cancer in both men and women and the single largest cause of cancer-related_mortality in the world it is disease with poor_prognosis and the survival statistics have scarcely improved since historical times the advent of targeted_therapies has caused an incremental increase in survival figures nevertheless significant progress in treatment outcomes need to be achieved before any perceptible improvement in overall_survival of lung cancer patients becomes_evident the use of active-specific immunotherapy or cancer vaccines for the treatment of lung cancer is still in its_infancy nevertheless several cancer vaccines have demonstrated clinical effects and improvements in overall_survival in phase_ii and phase_iii trials and several more clinical_trials are currently_ongoing this_review summarizes the recent_developments in nsclc vaccines

15481703

"Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Roberto Giacosa, Rosaria Santi, Augusto Vaglio, Laura Pavone, Francesco Ferrozzi, Rodolfo Passalacqua, Carlo Buzio
(Department of Clinical Medicine, Nephrology and Health Science, University of Parma, Parma, Italy.)
Acta Biomed

we here describe two patients with metastatic_renal cell cancer mrcc treated with immunotherapy in whom the metastases completely_regressed after period of progressive_disease the treatment schedule was based_on repeated_cycles of low-dose recombinant_interleukin-2 and recombinant_interferon-alpha and was never changed during the course of the disease the first patient received immunotherapy because of multiple_bilateral lung metastases progressive_disease with mediastinal_lymph node_involvement and an increased number of lung metastases was observed after months of regularly repeated therapy complete_regression was achieved after months of immunotherapy after immunotherapy cycles the second patient began immunotherapy because of three small lung metastases disease_progression was observed after three_cycles but complete_regression was obtained about months_after the start of immunotherapy after immunotherapy cycles long-term low-dose immunotherapy may bring_about an effective anti-tumour response even late in the course of the disease and after an initial disease_progression

22712796

Emerging new agents for the management of patients with non-small cell lung cancer.
Enrica Capelletto, Silvia Novello
(Department of Clinical and Biological Sciences, University of Turin - AOU San Luigi, Orbassano (TO) Italy.)
Drugs

lung cancer is one of the leading_causes of cancer-related_deaths worldwide non-small_cell lung cancer nsclc_accounts for at_least of all lung cancers and most cases present at an advanced stage with metastatic locally_advanced or recurrent_disease with greater_understanding of tumour biology number of targeted_agents have_been investigated for the treatment of advanced_nsclc these include insulin-like_growth factor inhibitors c-met inhibitors poly_adenosine diphosphate-ribose polymerase inhibitors histone_deacetylase inhibitors proapoptotic agents epidermal_growth factor_receptor inhibitors vaccines immunotherapy and hedgehog inhibitors this_article aims to provide an_overview of some of the emerging molecules for nsclc that have demonstrated interesting results in the past couple of years including descriptions of the molecular pathways of these drugs and their main location of action

11095409

Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
P Terheyden, J C Becker, E Kämpgen, E B Bröcker
(University Department of Dermatology, University of Würzburg, Germany.)
Melanoma Res.

the aim of this_study was the evaluation of both the antitumour_activity and toxicity of an immunochemotherapeutic regimen_consisting of interferon-alpha2b and interleukin-2 in combination with fotemustine for patients with metastatic melanoma to improve the penetration of fotemustine into the brain it was given immediately_after immunotherapy when the blood-brain_barrier is still disturbed of the patients treated three complete_remissions crs and one partial_remission pr were induced giving an objective_response rate of confidence_interval 6-46 the durations of the crs were and months the pr lasted for 59+ months the overall_survival times for the patients with cr were and 70+ months and 59+ months for the pr for nine patients confidence_interval 24-71 disease was stabilized for median period of months_range 2-18 months resulting in median_survival of months_range 10-41+ months no haematological_toxicity of world_health organization_grade or more was observed and in general toxicity was low in summary this immunochemotherapy regimen led to long-term_survival in occasional patients and about_half of the patients achieved stable_disease with prolonged treatment and progression-free_survival compared with nonresponding patients the occurrence of brain_metastases however was not prevented and in fact was the site of recurrence in those patients achieving_cr due to its low toxicity this protocol can_be applied at community_hospital level

24140068

Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression.
Qingli Zeng, Shaoli Li, Yanbin Zhou, Weijun Ou, Xingdong Cai, Longjuan Zhang, Wanling Huang, Lixia Huang, Qinqin Wang
(Department of Pulmonary Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.)
Cytokine

interleukin_il is novel proinflammatory_cytokine which has_been shown to play_an important_role in tumor growth and metastasis here_we discovered that il-32 was aberrantly over-expressed in lung adenocarcinoma tissues and cell_lines positive expression of il-32 significantly_correlated with the clinical staging and lymph_node and distant_metastases high expression of il-32 was an_independent indicator of poor_prognosis in lung adenocarcinoma patients moreover il-32-facilitated cell migration and invasion in vitro was mediated_through transactivation of the nuclear transcription_factor nf_κb signaling_pathway and subsequent upregulation of matrix_metalloproteinase mmp and mmp9 expression these studies demonstrate_that il-32 plays_role in the tumor-associated inflammatory_microenvironment and that overexpression of il-32 contributes to invasion and metastasis in primary lung adenocarcinoma suggesting_that it may have clinical_utility as prognostic_biomarker and potential target for immunotherapy in lung adenocarcinoma

14683586

IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
M Lee Lucas, Richard Heller
(Department of Medical Microbiology and Immunology, University of South Florida, Tampa, Florida 33612, USA.)
DNA Cell Biol.

interleukin-12_il-12 has_been evaluated in both preclinical and clinical immunotherapy protocols as potential therapy for melanoma however delivery of il-12 in the form of recombinant protein can result in severe_toxicity and gene therapy has had limited_success against b16_f10 murine_melanoma this_study investigated the therapeutic effect of delivering plasmid_encoding il-12 followed_by electroporation on primary and secondary tumors three treatments of intratumoral plasmid injection and electroporation resulted in of mice with b16_f10 melanoma tumors being tumor free for days cure the cured animals were resistant to challenge with b16 cells in separate experiment b16 cells were injected on the opposite flank of the treated tumor on the day of treatment eighty-seven percent of control mice developed distant tumor while only of mice receiving two or three electroporation treatments developed distant tumor for examination of tumor development in the lungs mice were injected_intravenously with b16_f10 cells then treated with injections of plasmid with or without electroporation only of mice receiving injections and electroporation developed nodules in the lungs compared to of mice in the no-treatment group the results_show that administration of plasmid_encoding il-12 with electroporation has therapeutic effect on primary tumors as_well as distant tumors and metastases

23948179

Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.
Yuan Yuanying, Niu Lizhi, Mu Feng, Wang Xiaohua, Zeng Jianying, Yao Fei, Jiang Feng, He Lihua, Chen Jibing, Li Jialiang, Xu Kecheng
(Fuda Cancer Hospital, Jinan University School of Medicine, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China.)
Cryobiology

currently there are no effective therapies for the treatment of metastatic non-small_cell lung cancer nsclc here_we conducted_retrospective study of patients to evaluate the therapeutic effects of combining cryosurgery chemotherapy and dendritic cell-activated cytokine-induced_killer cells dc-cik immunotherapy the overall_survival os after diagnosis of metastatic nsclc to patient death was assessed during 5-years follow-up_period os of patients who_received comprehensive cryotherapy was median_os months significantly_longer than that of patients who did_not received cryotherapy median_os months five treatment combinations were selected chemotherapy chemo-immunotherapy cryo-chemotherapy cryo-immunotherapy and cryo-chemo-immunotherapy combination of cryotherapy with either chemotherapy or immunotherapy lead to significantly_longer os months and months respectively compared to chemotherapy and chemo-immunotherapy months and months respectively however the median_os of patients who_underwent cryo-chemo-immunotherapy was significantly_longer months compared to the other treatment programs in conclusion combination of cryotherapy chemotherapy and dc-cik immunotherapy proved the best treatment_option for metastatic nsclc in this group of patients

15084384

Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors.
Alexandr V Bazhin, Marina S Savchenko, Olga N Shifrina, Sofia A Demoura, Svetlana Yu Chikina, Gabriele Jaques, Eugenia A Kogan, Alexandr G Chuchalin, Pavel P Philippov
(Laboratory of Biomedicine, Department of Cell Signalling, A.N. Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119992 Moscow, Russia.)
Lung Cancer

using immunoblotting with recombinant recoverin as an antigen we have examined serum_samples from individuals with small_cell lung carcinoma sclc patients non-small_cell lung carcinoma nsclc patients and non-malignant pulmonary disorders patients as_well as sera_from healthy_donors autoantibodies_against recoverin anti-rc were detected in sera_from patients with sclc of cases and from patients with nsclc about of cases only two anti-rc positive cases were detected in patients with non-malignant pulmonary disorders while no such cases were found in healthy_individuals immunohistochemical investigation of paraffin_sections of sclc and nsclc tumors revealed recoverin-positive reaction in sclc and nsclc sections despite the high specificity the low sensitivity less_than does_not allow serum anti-rc to be_considered as valuable marker of lung cancer however taking_into account the high occurrence of aberrant expression of recoverin in lung tumors this pna could_be considered as potential target for immunotherapy of lung cancer

16224275

A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
Lydia Koulova, Yelena Novik, Geralyn Caliendo, Peter Wiernik, Janice Dutcher
(Comprehensive Cancer Center at Our Lady of Mercy Medical Center, Bronx, New York 10466, USA.)
J. Immunother.

interleukin-2_il-2 has_been shown to produce durable_complete remission in patients with renal cell carcinoma_rcc phase study was conducted to evaluate the potential_therapeutic synergy as_well as the toxic_side effects of the concurrent administration of il-2 and granulocyte-macrophage_colony-stimulating factor_gm-csf in patients with advanced stage disease twenty-one_patients with unresectable or metastatic_rcc having an eastern oncology cooperative_group performance_status of or were_enrolled six patients had received_prior immunotherapy with interferon_ifn alpha ifn-gamma and il-12 whereas the remaining subjects were previously_untreated thirteen patients were assigned to moderate-dose bolus of il-2 at iu/kg every hours on days through and days through whereas patients were given il-2 as an intravenous continuous_infusion at dose of mu/m2/d on days through and days through subcutaneous gm-csf at microg/d on days through was administered_concomitantly with il-2 the median number of il-2 bolus doses was of scheduled whereas with the continuous_infusion of planned il-2 was given all patients received of gm-csf doses there were no complete or partial_responses in this_study of patients treated in the bolus il-2 arm had systemic progression of disease at to weeks developed metastasis in the brain at weeks and had_stable disease for and months among the subjects treated with continuous_infusion il-2 progressed with brain lesions at to weeks and had_stable disease at 6+ 8+ 15+ and 17+ months the median_survival for the whole group was months with range of to 40+ months there were no regimen-related deaths and most of the observed toxicities were grade and serious toxicities grade and included anemia atrial_fibrillation oliguria abnormal liver function and neurologic events like agitation or confusion the combination of recombinant_il-2 and gm-csf administered in the designed schedule and doses was not effective in patients with metastatic_rcc and may even interfere_with the therapeutic potential of moderate-dose il-2 and increase its adverse_events

12954119

Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity.
Francisco Robert, Elizabeth M Busby, Albert F LoBuglio
(Department of Medicine, Division of Hematology/Oncology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. pacorobertuab@cs.com)
Cancer Biother. Radiopharm.

the purpose of this retrospective_analysis was to evaluate the hematologic_toxicity and clinical_outcome of salvage_chemotherapy following y-cc49 radioimmunotherapy_rit in patients with non-small_cell lung cancer nsclc sixteen patients from total of who were_enrolled in phase_trial of y-cc49 monoclonal therapy were treated with post-rit salvage_chemotherapy at our_institution five patients had received chest radiation_therapy prior to rit and seven patients had prior chemotherapy the majority of these patients were treated with doses of of mci/m 8-20 mci/m and four of them received concurrent 96-hour taxol infusion the maximum_tolerated dose of this_study was exceeded at mci/m and grade thrombocytopenia/neutropenia were the dose-limiting_toxicities twelve patients received one chemotherapy_regimen as salvage_therapy and four patients had more_than one regimen four patients experienced reversible grade_neutropenia but no grade_thrombocytopenia was observed five patients had_stable disease the median_survival from start of salvage_therapy was months our_data suggest_that therapy with rit did_not significantly affect survival of these patients taking_into consideration the potential clinical_relevance of integration of rit with other treatment_modalities it is important to expand this clinical experience in order to support combined_modality strategies